Aberdeen Group plc Boosts Stake in Sionna Therapeutics, Inc. $SION

Aberdeen Group plc raised its holdings in Sionna Therapeutics, Inc. (NASDAQ:SION) by 27.4% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 950,547 shares of the company’s stock after purchasing an additional 204,583 shares during the quarter. Aberdeen Group plc owned 2.15% of Sionna Therapeutics worth $16,492,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. TD Asset Management Inc purchased a new stake in Sionna Therapeutics in the first quarter valued at $579,000. Goldman Sachs Group Inc. purchased a new stake in shares of Sionna Therapeutics in the 1st quarter valued at $667,000. Charles Schwab Investment Management Inc. purchased a new stake in shares of Sionna Therapeutics in the 1st quarter valued at $676,000. Woodline Partners LP purchased a new stake in shares of Sionna Therapeutics in the 1st quarter valued at $837,000. Finally, CenterBook Partners LP purchased a new stake in shares of Sionna Therapeutics in the 1st quarter valued at $1,195,000.

Insider Activity

In other news, Director Bruce Booth sold 66,105 shares of the stock in a transaction dated Monday, September 29th. The stock was sold at an average price of $30.09, for a total value of $1,989,099.45. Following the transaction, the director owned 796,259 shares in the company, valued at approximately $23,959,433.31. This represents a 7.67% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Michael Cloonan sold 17,574 shares of the stock in a transaction dated Tuesday, August 26th. The shares were sold at an average price of $24.96, for a total value of $438,647.04. Following the completion of the transaction, the chief executive officer owned 547,343 shares in the company, valued at approximately $13,661,681.28. The trade was a 3.11% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 211,239 shares of company stock worth $6,047,807. 3.90% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several research firms recently issued reports on SION. Weiss Ratings reiterated a “sell (d)” rating on shares of Sionna Therapeutics in a report on Wednesday, October 8th. Raymond James Financial began coverage on Sionna Therapeutics in a report on Tuesday, September 2nd. They issued a “strong-buy” rating and a $45.00 price objective on the stock. Jones Trading began coverage on Sionna Therapeutics in a report on Monday, September 8th. They issued a “buy” rating and a $46.00 price objective on the stock. Wall Street Zen upgraded Sionna Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 16th. Finally, Royal Bank Of Canada assumed coverage on Sionna Therapeutics in a report on Wednesday, September 3rd. They set a “sector perform” rating and a $22.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $38.00.

Sionna Therapeutics Stock Performance

Shares of SION opened at $29.94 on Wednesday. The firm’s fifty day simple moving average is $24.65 and its 200-day simple moving average is $18.12. Sionna Therapeutics, Inc. has a twelve month low of $7.26 and a twelve month high of $31.02.

Sionna Therapeutics (NASDAQ:SION) last posted its earnings results on Monday, August 11th. The company reported ($0.41) EPS for the quarter, beating the consensus estimate of ($0.68) by $0.27.

Sionna Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients.